Terumo Set To Build On Long-Term VAD Investments With Upcoming Trials
This article was originally published in PharmAsia News
Executive Summary
Terumo Corporation's long journey toward comercialization of the DuraHeart ventricular assist device is about to take a major step forward with the start of a U.S. "bridge-to-transplant" trial and the upcoming launch of a "destination therapy" trial